Publication | Closed Access
Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
54
Citations
24
References
2011
Year
The combination of NGR-hTNF 0.8 μg/m(2) with cisplatin 80 mg/m(2) showed favorable toxicity profile and promising antitumor activity.
| Year | Citations | |
|---|---|---|
Page 1
Page 1